entertainment -WSS

entertainment

author：hotspot 2025-10-01 01:50:49 - browse：1

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How one medical school became remarkably diverse
Next article： Why some fertility treatments produce more boy babies

WSS

The science behind Janet Jackson's pregnancy at 49

Disclosing genetic information: not as worrisome as once feared

Gene therapy has helped boys walk. Can scientists keep it that way?

Unmasking the 'centricity' illusion in clinical trials

Bird flu makes raw milk dangerous to consume, mouse study finds

Donald Trump's relentless attacks on special counsel Jack Smith

knowledge

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

Why drug prescriptions should include diagnoses

Hepatitis C has a cure — but many Americans still lack access to it

Lawsuit challenges CMS nursing home minimum staffing rule

Apple is now the first public company to be valued at $3 trillion

Beyond aggravation: Constipation is an American epidemic

Psychedelics group wrestles with new pharma identity

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Virginia high school admissions case could be legal follow

The Bio Revolution is changing business and society

focus

Ask STAT: What do you want to know about ChatGPT in medicine?

Why we need mandatory labeling of GMO products

Guardant Health colon cancer test endorsed by FDA advisory panel

Ozempic cut risk of death in diabetes patients with chronic kidney disease

With FDA staff opposed to Sarepta therapy, top official intervened

Disclosing genetic information: not as worrisome as once feared

hotspot

entertainment

focus

leisure time